Raia Drogasil S.A. (OTCMKTS:RADLY) Short Interest Update

Raia Drogasil S.A. (OTCMKTS:RADLYGet Free Report) was the recipient of a significant decline in short interest during the month of June. As of June 15th, there was short interest totaling 5,594 shares, a decline of 45.9% from the May 31st total of 10,333 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily volume of 125,379 shares, the days-to-cover ratio is currently 0.0 days.

Raia Drogasil Price Performance

OTCMKTS RADLY opened at $3.44 on Wednesday. Raia Drogasil has a fifty-two week low of $2.25 and a fifty-two week high of $5.34. The business has a fifty day moving average of $3.86 and a 200-day moving average of $4.38.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised Raia Drogasil to a “hold” rating in a report on Thursday, April 9th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, Raia Drogasil currently has an average rating of “Hold”.

Check Out Our Latest Stock Report on RADLY

About Raia Drogasil

(Get Free Report)

Raia Drogasil SA is a leading Brazilian retail pharmacy operator, offering a comprehensive range of prescription and over-the-counter medications, health and wellness products, personal care and beauty items, as well as a selection of convenience goods. The company’s network of stores operates under the Raia and Drogasil banners, serving diverse consumer needs across major urban centers. Complementary services include in-store prescription dispensing, compounding pharmacies and health screening programs such as blood pressure and glucose monitoring.

The company was formed in 2011 through the merger of two established Brazilian pharmacy chains, Drogasil and Droga Raia, each with origins dating back several decades.

Featured Articles

Receive News & Ratings for Raia Drogasil Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raia Drogasil and related companies with MarketBeat.com's FREE daily email newsletter.